Bruker Corp (BRKR) is a global leader in scientific instruments manufacturing and analytical software development for molecular and materials research, diagnostic and applied analysis. Founded in 1960 by physicist Dr. Gunther Laukien, the company is headquartered in Billerica, Massachusetts.
Bruker Corp. operates in two segments: Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST). BSI provides innovative scientific instruments and analytical solutions to explore life and materials at molecular, cellular, and microscopic levels. It supports research in the areas like life sciences research, pharmaceuticals, biotechnology, agricultural and food safety, and forensics. It constitutes of three divisions; Bruker BioSpin, Bruker CALID, and Bruker Nano.
Meanwhile, the BEST segment develops and manufactures advanced superconductor materials, devices, and system solutions. It offers scientific instrumentation used for energy management, mobile power, transportation, and other technological research applications.
Publicly traded on the NASDAQ, Bruker Corp. is known for its high-performance scientific instruments and high-value analytical and diagnostic solutions that enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In addition, their instruments are used in a broad range of industries including pharmaceuticals, biotechnology, and commodities food testing, thus enhancing their customer base.
Over the decades, Bruker has carved a niche for itself with its innovative yet user-friendly solutions that have had a profound impact in the therapeutic and diagnostic market. The company has a strong presence worldwide with additional manufacturing, sales, and service facilities located throughout Europe, North America, and Asia.
In terms of innovations, Bruker is at the forefront of developing advanced technologies. They recently rolled out the world’s first 1.2 GHz high-resolution protein NMR (Nuclear Magnetic Resonance), which is an achievement in technology and performance.
In their annual report, the company consistently highlights its commitment to ethical business conduct and sustainable practices, valuing its global workforce composed of diverse talents as their driving force.
Bruker Corp has experienced continuous growth throughout the years, a testament to their commitment in delivering powerful, productive, and customer-oriented solutions that keep them at the leading edge of scientific research and related industries. It plays a pivotal role in improving the efficiency and effectiveness of the scientific process, accelerating scientific innovation, and enhancing the quality of life throughout the world.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Bruker Corp (BRKR) shares dropped 4.3% to $56.98, yet its GF Score of 84/100 indicates strong overall performance. The stock is considered slightly undervalued with a GF Value of $60.24, despite unprofitability and recent insider selling worth $3.6 million. Investors are advised to exercise caution and conduct further evaluation due to these mixed signals.
Ceredex Value Advisors LLC has acquired 213,450 shares of Bruker Corporation (NASDAQ:BRKR) valued at approximately $12.8 million. Other institutional investors also adjusted their positions, with hedge funds and institutional investors collectively owning 79.52% of the company. Bruker reported an EPS of $0.49, surpassing estimates, and declared a quarterly dividend of $0.05 per share, while analysts maintain a "Moderate Buy" rating with a target price of $56.64.
Advisors Capital Management LLC has acquired a new position in Bruker Corporation, purchasing 81,937 shares valued at approximately $4.93 million. This makes them owners of about 0.05% of Bruker's stock. Other institutional investors have also adjusted their holdings, with significant increases from Orbis Allan Gray Ltd, Pallas Capital Advisors LLC, State Street Corp, AQR Capital Management LLC, and Sculptor Capital LP.
Bruker Corporation (NASDAQ:BRKR) has received a consensus "Moderate Buy" rating from fourteen brokerages, with an average 12-month price target of $56.64. The company recently exceeded earnings expectations with $0.49 EPS against a $0.38 consensus but fell short on revenue estimates, reporting $838.5 million. Several firms have adjusted their price targets, and Bruker also declared a quarterly dividend of $0.05 per share.
Old West Investment Management LLC has acquired a significant new stake of 667,103 shares in Bruker Corporation (NASDAQ:BRKR), valued at approximately $40.1 million. This makes Bruker its largest portfolio holding, representing 4.3% of its assets and about 0.44% of Bruker's total shares. Bruker recently reported strong quarterly earnings, beating EPS estimates, though revenue slightly missed expectations, while analysts hold a "Moderate Buy" consensus rating for the stock.